The metabotropic glutamate receptor (mGluR) mGluR5 subtype plays a critical role in regulating the rewarding effects of drugs of abuse and recent studies suggest that selective mGluR5 antagonists may provide an exciting new approach for treatment of addictive disorders. We have identified multiple new mGluR5 antagonists, including multiple unique scaffolds as well as compounds based on existing scaffolds that have novel activities. Most notably, we discovered a novel class of compounds that act as highly selective partial antagonists of mGluR5. Unlike partial agonists that have been identified for other receptors, these compounds do not activate the receptor to any level. However, they partially block activation of the receptor by glutamate without fully blocking receptor activation. We now have multiple partial antagonists that block mGluR5 with a range of activities from 10% to 90% inhibition when the allosteric binding site on the receptor is fully occupied. This exciting breakthrough would not be possible with traditional competitive orthosteric site antagonists but is achieved by targeting the allosteric antagonist site. By employing high throughput medicinal chemistry techniques we will optimize these screening leads into compounds suitable for proof of concept studies. These novel compounds will provide an unprecedented opportunity for our labs to determine whether partial blockade of mGluR5 will have effects in animal models that predict efficacy in treatment of cocaine abuse or whether complete blockade of the receptor is required. Also, these agents will allow us to directly evaluate the adverse effects of mGluR5 antagonists that possess different levels of mGluR5 blockade. In addition, our new understanding of partial antagonist activity will allow us to optimize compounds belonging to existing partial antagonist scaffolds as well as novel chemical classes to identify optimal properties to be used as research tools and drug leads. This research has direct relevance to the mission of NIDA and has the potential to impact human health directly. Our goal for this project is to develop a partial mGluR5 antagonist with an acceptable profile for preclinical and ultimately clinical development that may become a new drug to treat addictive disorders.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-MXS-M (17))
Program Officer
Shih, Ming L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Schools of Medicine
United States
Zip Code
Gregory, Karen J; Nguyen, Elizabeth D; Malosh, Chrysa et al. (2014) Identification of specific ligand-receptor interactions that govern binding and cooperativity of diverse modulators to a common metabotropic glutamate receptor 5 allosteric site. ACS Chem Neurosci 5:282-95
Conn, P Jeffrey; Lindsley, Craig W; Meiler, Jens et al. (2014) Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov 13:692-708
Bates, Brittney S; Rodriguez, Alice L; Felts, Andrew S et al. (2014) Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorg Med Chem Lett 24:3307-14
Amato, Russell J; Felts, Andrew S; Rodriguez, Alice L et al. (2013) Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction. ACS Chem Neurosci 4:1217-28
Noetzel, M J; Gregory, K J; Vinson, P N et al. (2013) A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol Pharmacol 83:835-47
Engers, Darren W; Lindsley, Craig W (2013) Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders. Drug Discov Today Technol 10:e269-76
Gregory, Karen J; Nguyen, Elizabeth D; Reiff, Sean D et al. (2013) Probing the metabotropic glutamate receptor 5 (mGluýýý) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology. Mol Pharmacol 83:991-1006
Felts, Andrew S; Rodriguez, Alice L; Morrison, Ryan D et al. (2013) Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorg Med Chem Lett 23:5779-85
Melancon, Bruce J; Hopkins, Corey R; Wood, Michael R et al. (2012) Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem 55:1445-64
Mueller, Ralf; Dawson, Eric S; Meiler, Jens et al. (2012) Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor?5 (mGlu?): from an artificial neural network virtual screen to an in vivo tool compound. ChemMedChem 7:406-14

Showing the most recent 10 out of 23 publications